Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Anticoagulants
/ administration & dosage
COVID-19
Cohort Studies
Coronavirus Infections
/ diagnosis
Critical Care
/ methods
Critical Illness
/ mortality
Extracorporeal Membrane Oxygenation
/ adverse effects
Female
France
Hospital Mortality
/ trends
Hospitals, University
Humans
Intensive Care Units
Male
Pandemics
Pneumonia, Viral
/ diagnosis
Retrospective Studies
Risk Assessment
Severe Acute Respiratory Syndrome
/ diagnostic imaging
Survival Rate
Tertiary Care Centers
Tomography, X-Ray Computed
/ methods
Treatment Outcome
Venous Thromboembolism
/ drug therapy
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
4
7
2020
medline:
29
9
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
The main objective of the study was to determine the prevalence of venous thromboembolism events in patients infected with severe acute respiratory syndrome coronavirus 2 requiring venovenous extracorporeal membrane oxygenation. The secondary objective was to compare venous thromboembolism events and coagulation variables in patients requiring venovenous extracorporeal membrane oxygenation according to the pathogen. Retrospective observational analysis at a single center. Tertiary referral university teaching hospital. Patients with severe acute respiratory syndrome coronavirus 2-related severe acute respiratory distress syndrome requiring venovenous extracorporeal membrane oxygenation therapy with an injected CT scan performed after extracorporeal membrane oxygenation retrieval. None. We included 13 severe acute respiratory syndrome coronavirus 2 patients requiring venovenous extracorporeal membrane oxygenation. All of these patients experienced venous thromboembolism: 10 patients (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism. Eleven patients (84.6%) had cannula-associated deep vein thrombosis. A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (53.8%), a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9%), and six patients (46.2%) had both femoral and jugular cannula-associated deep vein thrombosis. A pulmonary embolism was found in three patients (23.1%). No patient had central venous catheter-related deep vein thrombosis. One patient had thrombotic occlusion of the centrifugal pump, and one had oxygenator thrombosis requiring circuit replacement. Three patients (23.1%) had significant bleeding. Three patients (23.1%) had laboratory-confirmed heparin-induced thrombocytopenia, and all of them developed cannula-associated deep vein thrombosis. These three patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump thrombosis. The mean activated partial thromboplastin time ratio was higher in the severe acute respiratory syndrome coronavirus 2 group than in the influenza group and the community-acquired pneumonia group (1.91 vs 1.48 vs 1.53; p = 0.001), which was also found in regard to the percentage of patients with an activated partial thromboplastin time ratio greater than 1.8 (47.8% vs 20% vs 20.9%; p = 0.003) and the mean prothrombin ratio (86.3 vs 61.6 vs 67.1; p = 0.003). There was no difference in baseline characteristics or venous thromboembolism events. We report a 100% occurrence of venous thromboembolism in critically ill patients supported by venovenous extracorporeal membrane oxygenation for severe acute respiratory syndrome coronavirus 2-related acute respiratory distress syndrome using CT scan imaging despite a high target and close monitoring of anticoagulation.
Identifiants
pubmed: 32618700
doi: 10.1097/CCM.0000000000004504
pmc: PMC7328443
pii: 00003246-202010000-00042
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e971-e975Références
Br J Anaesth. 2020 Aug;125(2):e260-e262
pubmed: 32414510
N Engl J Med. 2020 Jul 16;383(3):288-290
pubmed: 32369280
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Crit Care Med. 2015 Dec;43(12):e581-4
pubmed: 26308437
Crit Care Med. 2020 Feb;48(2):192-199
pubmed: 31939787
Lancet Respir Med. 2019 Feb;7(2):108-110
pubmed: 30642778
ASAIO J. 2017 Sep/Oct;63(5):588-591
pubmed: 28857905